The Rise of Psilocybin Use in the United States: A Multisource Observational Study - Karilynn Rockhill; Joshua C. Black; Michael S. Ladka; Kanku B. Sumbundu; Heather Olsen; Jennifer S. Jewell; Joshua C. Hunt; R. Cameron Wolf; Karuna Nerurkar; Richard C. Dart; Andrew A. Monte (Annals of Internal Medicine, 2025)

Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials. - Mimms C; Sotelo K; Khaliq AS. (2025)

Roadmap for Equitable Access and Responsible Use of Psilocybin-Assisted Psychotherapy in Palliative Care - Michel Dorval; Sue-Ling Chang; Houman Farzin; Olivia Nguyen; Jean-François Stephan; Diane Tapp; P. Deschamps; Yann Joly; Florence Moureaux; Robert Foxman; Marianne Masse-Grenier; Jean-Sébastien Fallu (Palliative Medicine Reports, 2025)

Psilocybin and ketamine affect novel neuropeptides gene expression in the rat hypothalamus - Artur Pałasz; Marta Pukowiec; Katarzyna Bogus; Aleksandra Suszka-Świtek; Łukasz Filipczyk; Kinga Mordecka-Chamera; John J. Worthington; Maria Sygidus; Adam Wojtas; Agnieszka Bysiek; Krystyna Gołembiowska (Journal of Psychopharmacology, 2025)

Regulatory Alignment of Psilocybin Clinical Trials in Major Depressive Disorder on ClinicalTrials.gov: A Cross-Sectional Analysis - Damian Świeczkowski; Aleksander Kwaśny; Michał Pruc; Zuzanna Gaca; Łukasz Szarpak; Wiesław Jerzy Cubała (Pharmacopsychiatry, 2025)

A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Psilocybin Administration in Concert With Psychotherapy Among Adult Patients With Fibromyalgia - Kevin Boehnke (ClinicalTrials.gov, 2025)

Psilocybin biosynthesis enhancement through gene source optimization - Madeleine R. Keller; Madeline G. McKinney; Abhishek K. Sen; Felicia G Guagliardo; Elle B. Hellwarth; Khondokar Nowshin Islam; Nicholas A. Kaplan; William J. Gibbons; Grace E Kemmerly; Chance Meers; Xin Wang; J. Andrew Jones (Metabolic Engineering, 2025)

Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review. - Meshkat S; Malik G; Zeifman RJ; Swainson J; Balachandra K; Reichelt AC; Zhang Y; Burback L; Winkler O; Greenshaw A; Vermetten E; Mayo LM; et al. (2025)

Psilocin alleviates acute itch in mice: possible involvement of 5-HT2A receptors and kynurenine pathway - Arya Afrooghe; Elham Ahmadi; Ali Lesani; Mahya Soleymani Mehranjani; Mohammad Elahi; Mohammadreza Babaei; Maryam Shayan; Hamed Shafaroodi; Razieh Mohammad Jafari; Alireza Foroumadi; Mohammad Amin Manavi; Ahmad Reza Dehpour (Naunyn-Schmiedeberg s Archives of Pharmacology, 2025)

The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training - Felix Mueller (ClinicalTrials.gov, 2025)

Assessing the potential cardiovascular risk of microdosing the psychedelic LSD in mice - Effinger DP; Schalk SS; King JL; Strong JR; O’Connell CK; Calderon JR; McCorvy JD; Thompson SM. (bioRxiv, 2025)

PsiConnect: A Multimodal Neuroimaging Study of Psilocybin-Induced Changes in Brain and Behaviour - Novelli L; Stoliker D; Barta T; Greaves MD; Chopra S; Jackson J; Kwee J; Williams ML; Razi A. (bioRxiv, 2025)

Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study). - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2025)

Psilocybin as a Tool in the Management of Palliative Care: An Historical, Pharmacological, and Clinical Approach - Turizo Smith AD; Botero Jsramillo N; Berrio Cuartas DM. (Preprints.org, 2025)

Targeting Phantom Pain with Psilocybin: Toward Integration with Adaptive Sensory Technologies. - Kargbo RB. (2025)

Exploring psilocybin's role in mental health and palliative medicine: a path to improved well-being. - Umbacia MA; Leon MX; Quintero JM; Castro LM; Paez V; Dodd S; Bustos RH. (2025)

458. Microdoses of Psilocybin Combined With Eugenol are Absorbed and Induce Unique Cerebellar Gene Expression - Chuck T. Chen; Aidan D Tyrrell; Darryl Hudson; Ralph Landau; Adam H. Metherel; Richard P. Bazinet (Biological Psychiatry, 2025)

630. Synthetic Psilocybin (COMP360) for Chronic Active Suicidal Ideation: An Open-Label Study - Scott Aaronson; Tammy Miller; Audrey Shoultz; Bryce Lund; Jeffrey LaPratt; Margo Lauterbach; Kim Swartz; Andrew van der Vaart (Biological Psychiatry, 2025)

194. Improving Workplace and Psychosocial Function in Treatment-Resistant Depression: Exploratory Outcomes From an Open-Label Feasibility Trial of Psilocybin-Assisted Psychotherapy - Orly Lipsitz; Joshua D. Rosenblat (Biological Psychiatry, 2025)

187. Changes in Symptoms of Anhedonia With Psilocybin-Assisted Psychotherapy: A Secondary Analysis of a Randomized Clinical Trial for Treatment-Resistant Depression - Erica Kaczmarek; Nelson B. Rodrigues; Noah Chisamore; Zoe Doyle; Roger S. McIntyre; Rodrigo B. Mansur; Joshua D. Rosenblat (Biological Psychiatry, 2025)

186. Assessing Cognitive Outcomes in Treatment-Resistant Depression Following Psilocybin-Assisted Psychotherapy - Danica E. Johnson; Erica Kaczmarek; Noah Chisamore; Orly Lipitz; Zoe Doyle; Rodrigo B. Mansur; Roger S. McIntyre; Joshua D. Rosenblat (Biological Psychiatry, 2025)

58. Acute Behavioral Effects of Psilocybin and Its Pharmacokinetics in Nonhuman Primates - Ashton Barber; Sydney Gifford; Patrick H. Roseboom; Jonathan A. Oler; Nate Jones; Molly C. Pellitteri-Hahn; Cameron O. Scarlett; Cody J. Wenthur; Paul R. Hutson; Ned H. Kalin (Biological Psychiatry, 2025)

166. Dynamic Mediodorsal Thalamus Activity Predicts and Reflects Longitudinal Treatment Outcomes in Psilocybin Therapy for Treatment-Resistant Depression - Xue Zhang; Emily Zhai; Claire Bertrand; Sara Ellis; Isabelle Wydler; Anna J. Donnelly; Trisha Suppes; Leanne M. Williams (Biological Psychiatry, 2025)

13. Safety, Feasibility, and Tolerability of Psilocybin in Older Adults With Amnestic MCI: Preliminary Data From a SV2a PET Imaging Study - Danielle Bukovsky; Aron Amaev; Jianmeng Song; Edgardo Torres Carmona; S. Lauren Kyte; Fumihiko Ueno; Vincenzo De Luca; Christopher R. Bowie; Alastair J. Flint; Muhammad Ishrat Husain; Ariel Graff-Guerrero; Philip Gerretsen (Biological Psychiatry, 2025)

595. Psilocybin-Assisted Therapy for Relapse Prevention in Alcohol Use Disorder: A RCT - Nathalie M. Rieser; Raoul Bitar; Halm Simon; Christina Rossgoderer; Ladina P Gubser; Maeva Thévenaz; Yara Kreis; Robin von Rotz; Carlos Nordt; Flora Moujaes; Etna Engeli; Andres Ort; et al. (Biological Psychiatry, 2025)

323. Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation - Noah Chisamore; Erica Kaczmarek; Zoe Doyle; Danica E. Johnson; Rodrigo B. Mansur; Roger S. McIntyre; Joshua D. Rosenblat (Biological Psychiatry, 2025)

Psilocybin-assisted Interpersonal Therapy for Depression - University of Otago (ClinicalTrials.gov, 2025)

The Emergence of Psilocybin in Psychiatry and Neuroscience. - Omidian H; Omidian A. (2025)

A multi-institutional investigation of psilocybin’s effects on mouse behavior - Lu OD; White K; Raymond K; Liu C; Klein AS; Green N; Vaillancourt S; Gallagher A; Shindy L; Li A; Wallquist K; Li R; et al. (bioRxiv, 2025)

In Vitro Psilocybin Synthesis by Co-Immobilized Enzymes - Tim Schäfer; Alexander M. Sherwood; Thomas A. Kirkland; Thomas Krüger; Jakob Worbs; Olaf Kniemeyer; Markus Gressler; Dirk Hoffmeister (Chemistry - A European Journal, 2025)

Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial - Ellen Bradley; Kimberly Sakai; Gisele Fernandes-Osterhold; Balázs Szigeti; Connie Ludwig; Jill L. Ostrem; Caroline M. Tanner; Meredith Bock; Katiah Llerena; Patrick R. Finley; Aoife O’Donovan; José Rafael P. Zuzuárregui; et al. (Neuropsychopharmacology, 2025)

Psilocybin’s Effects on Headache Frequency are Not Related to Acute Psychedelic Effects or Measures of Mental Health: Secondary Analysis of Clinical Trials in Migraine and Cluster Headache (P7-12.001) - Emmanuelle A. D. Schindler; Christopher Gottschalk; Deepak Cyril D’Souza (Neurology, 2025)

The compulsive eating paradigm: can psychedelics help in treating obesity? - Ammineni D; Park R. (2025)

Letter to the editor: Comments on 'Striking long-term beneficial effects of single-dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming' by Brownstien et al. (2024). - Gattuso JJ; Wilson C; Hannan AJ; Renoir T. (2025)

Therapeutic Potential of Psilocybin-Assisted Therapy in Hospice and Palliative Care - Ana Cláudia Mesquita Garcia (Revista Cacto - Ciência Arte Comunicação em Transdisciplinaridade Online, 2025)

Potential therapeutic effects of psychedelics in small doses: Is there a role for microdosing in psychiatry? - Totomanova I; Haijen ECHM; Hurks PPM; Ramaekers JG; Kuypers KPC. (2025)

Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models. - Agnorelli C; Spriggs M; Godfrey K; Sawicka G; Bohl B; Douglass H; Fagiolini A; Parastoo H; Carhart-Harris R; Nutt D; Erritzoe D. (2025)

Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors - Ling-Xiao Shao; Clara Liao; Pasha A. Davoudian; Neil K. Savalia; Quan Jiang; Cassandra Wojtasiewicz; Diran Tan; Jack D. Nothnagel; Rongjian Liu; Samuel C. Woodburn; Olesia M. Bilash; Hail Kim; et al. (Nature, 2025)

Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial - Nathalie M. Rieser; Raoul Bitar; Simon Halm; Christina Rossgoderer; Ladina P Gubser; Maeva Thévenaz; Yara Kreis; Robin von Rotz; Carlos Nordt; Monika Visentini; Flora Moujaes; Etna Engeli; et al. (Universität Zürich, ZORA, 2025)

Pictorial Representation of Illness and Self Measure: A Putative Transdiagnostic Tool for Evaluating Therapeutic Effects of Psilocybin-Assisted Therapy in Fibromyalgia - Niloufar Pouyan; Jacob S. Aday; David G. Williams; Kevin F. Boehnke; Steven E. Harte (Journal of Pain, 2025)

Psilocybe cubensis y Panaeolus cyanescens (Basidiomycota, Agaricales), dos especies de hongos alucinógenos en el NE de Argentina - Adriana Judit Batista; Hugo A. Almirón; Gisela Forlín; Natalia A. Ramírez; Orlando F. Popoff; Nicolás Niveiro (Boletín de la Sociedad Argentina de Botánica, 2025)

Psilocybin Has No Analgesic Properties in Multiple Mouse Models of Acute and Chronic Pain - Nicholas Gregory; Tyler E. Girard; Akila Ram; Austen B. Casey; Robert C. Malenka; Vivianne L. Tawfik; Boris D. Heifets (Journal of Pain, 2025)

Clarifying the legal landscape of psilocybin regulation: A medico-legal perspective - Octavian Brinzei (Drug Science Policy and Law, 2025)

Psilocybin mushrooms (“Magic Mushrooms”) (Organization of Teratology Information Specialists (OTIS), Brentwood (TN), 2025)

A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care. - Miller M; Meyers M; Martin A; Napolitano S; Dorsen C; Penn A; Rosa WE (Journal of hospice and palliative nursing: JHPN: the official journal of the Hospice and Palliative Nurses Association, 2025)

Psilocybin Dispensaries and Online Health Claims in Canada - Jenna Matsukubo; Sarah Dickson; Jennifer Xiao; Erik Loewen Friesen; Marco Solmi; Jess G. Fiedorowicz; Benedikt Fischer; Daniel T. Myran (JAMA Network Open, 2025)

Psilocybin Dispensaries and Advertising-Buyer Beware - Paul R. Hutson (JAMA Network Open, 2025)

De Novo Biosynthesis of Antidepressant Psilocybin in Escherichia coli - Zhangrao Huang; Yongpeng Yao; Rong Di; Jianchao Zhang; Yuanyuan Pan; Gang Liu (Microbial Biotechnology, 2025)

Psilocybin has a narrow therapeutic window as an antidepressant treatment - Lenka Seillier; Barbora Čechová; Alexandre Seillier; Romana Šlamberová (Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2025)

Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement - Vanessa L. Beesley; Tom Kennedy; Fiona Maccallum; Margaret Ross; Renee Harvey; Susan L. Rossell; Jerome Sarris; Daniel Perkins; Rachel Ε. Neale; James Bennett-Levy; Shevaugn Johnson; Hanna Beebe; et al. (BMJ Open, 2025)

Effects of a single dose of psilocybin on diet-induced weight loss in obese mice - Keenan R; Haque R; Jin X; Mustafa T; Homman-Ludiye J; Elysee K; Wee ZS; Simonds S; Foldi C; Cowley M. (Research Square, 2025)

Utilizing Psychedelics to Enhance Well-Being: A Systematic Review. - Thomson S; Thomacos N. (2025)

Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN - Unity Health Toronto (ClinicalTrials.gov, 2025)

Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases (PsyArXiv, 2025)

Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases - Heller NH; Barrett FS; Buchborn T; Collerton D; Dupuis D; Halberstadt AL; Jardri R; Noorani TN; Preller KH; Taylor J; Waters F; Winston B; et al. (PsyArXiv, 2025)

The effect of low-dose psilocybin on brain neurotransmission and rat behavior - Agnieszka Bysiek; Adam Wojtas; Izabela Szpręgiel; Agnieszka Wawrzczak-Bargieła; Marzena Maćkowiak; Krystyna Gołembiowska (Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2025)

Psilocybin-assisted therapy leads to personality shifts in patients with alcohol use disorder (The Brown University Psychopharmacology Update, 2025)

Ayahuasca in the treatment of the consequences of chronic childhood sexual abuse in a religious community - Turkia M. (PsyArXiv, 2025)

Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study) - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2025)

Ayahuasca in the treatment of the consequences of chronic childhood sexual abuse in a religious community (PsyArXiv, 2025)

Existing evidence for the use of psychedelics in patients with cancer and other serious illness: A narrative review. - Bires J. (2025)

Intravenous psilocybin induces dose-dependent changes in functional network organization in rat cortex - Brian H. Silverstein; Nicholas Kolbman; Amanda Nelson; Tiecheng Liu; Peter R. Guzzo; Jim Gilligan; UnCheol Lee; George A. Mashour; Giancarlo Vanini; Dinesh Pal (Translational Psychiatry, 2025)

Pharmacokinetics of Psilocybin: A Systematic Review. - Meshkat S; Al-Shamali H; Perivolaris A; Tullu T; Zeifman RJ; Zhang Y; Burback L; Winkler O; Greenshaw A; Husain MI; C Reichelt A; Vermetten E; et al. (2025)

Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l’étude - Noah Chisamore; Erica Kaczmarek; Zoe Doyle; Danica E. Johnson; Geneva Weiglein; Shakila Meshkat; Ryan M. Brudner; Marc G. Blainey; Jeremy Riva-Cambrin; Roger S. McIntyre; Joshua D. Rosenblat (The Canadian Journal of Psychiatry, 2025)

Classic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges. - Ghaznavi S; Richter SG. (2025)

Anhedonia: Current and future treatments. - Serretti A. (2025)

LPS-Induced Liver Inflammation Is Inhibited by Psilocybin and Eugenol in Mice - Gregory Ian Robinson; Marta Gerasymchuk; Timur Zanikov; Esmaeel Ghasemi Gojani; Shima Asghari; Alyssa Groves; Lucie Haselhorst; Sanjana Nandakumar; Cora Stahl; Ceejay Cruz; Mackenzie Cameron; Yeva Zahoruiko; et al. (Pharmaceuticals, 2025)

Structural basis for psilocybin biosynthesis - Chunyan Meng; Wenting Guo; Xiao Chuan; Yan Wen; Xudong Zhu; Qingrong Zhang; Yuxuan Liang; Hongwei Li; Sha Xu; Yuntan Qiu; Haitao Chen; Wei-Jye Lin; et al. (Nature Communications, 2025)

The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial - Henry J; Giribaldi B; Nutt DJ; Erritzoe D; Carhart-Harris R; Lyons T. (medRxiv, 2025)

Is there a place for psychedelics in sports practice? - Portes MAM; Werle I; Bertoglio LJ. (2025)

Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning-Based Advanced Perspectives. - Kim SH; Yang S; Jung J; Choi J; Kang M; Joo JY. (2025)

Synthesis and In Vitro Profiling of Psilocin Derivatives: Improved Stability and Synthetic Properties - Julia Eklund; Ulf Bremberg; Jessica Larsson; Edvard Torkelsson; Johan Wennerberg; Symantha Zandelin; Luke R. Odell (Journal of Medicinal Chemistry, 2025)

An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study - McMaster University (ClinicalTrials.gov, 2025)

Molecular Imaging Study of Harmine/DMT: a Basic Research Approach - Insel Gruppe AG; University Hospital Bern (ClinicalTrials.gov, 2025)

Psilocybin in Alcohol Use Disorder With Comorbid Depression - Centre Hospitalier Universitaire de Nīmes (ClinicalTrials.gov, 2025)

A Randomized, Placebo-controlled Trial of Psychedelic-assisted Psychotherapy With Single Dose Psilocybin for Frontline Clinicians Experiencing COVID-related Symptoms of Depression and Burnout - University of Washington (ClinicalTrials.gov, 2025)

The psychedelic psilocybin and light exposure have similar and synergistic effects on gene expression patterns in the visual cortex - Ram Harari; Dmitriy Getselter; Evan Elliott (Molecular Brain, 2025)

Exploring the potential of psychedelic-assisted psychotherapy for moral injury: A scoping review. - Kurkova V; Winkler O; Greenshaw A; Jetly R; Swainson J; Lodewyk K; Saghafi P; Dennett E; Burback L. (2025)

A Modern Overview of the Potential Therapeutic Effects of Psilocybin in the Treatment of Depressive Disorders, Treatment-Resistant Depression, and End-of-Life Distress. - Dino F. (2025)

IUPHAR Article: Psilocybin induces long-lasting effects via 5-HT2A receptors in mouse models of chronic pain - Eda Köşeli; Belle Buzzi; Torin Honaker; Yogesh Rakholia; Melissa J. Lewis; Maya Gaines-Smith; Alaina M. Jaster; Javier González-Maeso; M. Imad Damaj (Pharmacological Research, 2025)

Therapeutic Potential of Psilocybin for Treating Neuropsychiatric Long COVID Symptoms: A Reddit Investigation - Lukas Bobak; Ian Dorney; Alexsandra Kovacevich; Brian S. Barnett (Journal of Psychoactive Drugs, 2025)

BIOLOGICAL ACTIVITY OF PSILOCYBIN EXTRACTS FROM THE FRUITING BODIES OF PSILOCYBE CUBENSIS ANTIOXIDANT AND ANTIMICROBIAL POTENTIAL - Shimal Yonuis Abdulhadi; Noor Alaubidi; Walla H. Shuker; Sanabel A. Abd Almajeed (Journal of Microbiology Biotechnology and Food Sciences, 2025)

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety - Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (ClinicalTrials.gov, 2025)

PSYCHEDELIC PHARMACOLOGY IN PSYCHIATRY: THE MECHANISMS AND THERAPEUTIC POTENTIAL OF PSILOCYBIN, MDMA, AND LSD IN MENTAL HEALTH DISORDERS - Dr Hafiz Shafique Ahmad; Muhammad Waqar Ali; Usman Ul Haq (Journal of medical & health sciences review., 2025)

Psychedelics and autobiographical memory - Six open questions - Kangaslampi S; Lietz MP. (PsyArXiv, 2025)

Psychedelics Align Brain Activity with Context - Stoliker D; Novelli L; Khajehnejad M; Biabani M; Greaves MD; Barta T; Williams M; Chopra S; Bazin O; Simonsson O; Chambers R; Barrett F; et al. (bioRxiv, 2025)

Lasting effect of psilocybin on sociability can be blocked by DNA methyltransferase inhibition - Song C; Chang T; Buchborn T; Knöpfel T. (bioRxiv, 2025)

Psychedelics and autobiographical memory - Six open questions (PsyArXiv, 2025)

Revealing Changes in Linear and Nonlinear Functional Connectivity After Psilocybin and Escitalopram Treatment in Patients with Depression - Quah S; Glick C; Roseman L; Pasquini L; Carhart-Harris R; Saggar M. (bioRxiv, 2025)

Psilocybin for disorders of consciousness: A case-report study - Paolo Cardone; Pablo Núñez; Naji Alnagger; Charlotte Martial; Glenn van der Lande; Robin Sandell; Robin Carhart-Harris; Olivia Gosseries (Clinical Neurophysiology, 2025)

Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action. - Repple J; Bayas M; Möser C; Kobayashi NF; Reif A. (2025)

Exploring Public Sentiments of Psychedelics Versus Other Substances: A Reddit-Based Natural Language Processing Study - Biba B; O'Shea B. (PsyArXiv, 2025)

Extraction Yields of Psilocybin and Psilocin: A Short Review of Current Methods and Their Implications. - Galdino TP; Oliveira LC; Luz MA; Jesus RA; Lima EPN; Torres MCM; Sivieri K; Afonso VI; Delgado JMPQ; Lima AGB; Silva SML; Fook MVL. (2025)

Psychedelics and Eating Disorders: Exploring the Therapeutic Potential for Anorexia Nervosa and Beyond. - Hu S; Lin C; Wang H; Wang X. (2025)

Exploring Public Sentiments of Psychedelics Versus Other Substances: A Reddit-Based Natural Language Processing Study (PsyArXiv, 2025)

Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes. - Modzelewski S; Stankiewicz A; Waszkiewicz N; Łukasiewicz K. (2025)

Risks of using psilocybin in treatment of treatment-resistant depression - Michał Orzechowski; Joanna Orzechowska; Paulina Fijałek; Jan Karczmarz; Aleksandra Paprocka; Marika Gutowska; Agnieszka Kosińska; Urszula Świrk; Wiktoria Belcarz; Katarzyna Kalinowska (Journal of Education Health and Sport, 2025)

Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2025)

Further education in psychedelic-assisted therapy - experiences from Switzerland. - Aicher HD; Müller F; Gasser P. (2025)

Could psilocin rescue chronic, stress-accelerated, transcriptional aging in brain? - Craig; Danny R; Blalock; Eric M. (UKnowledge (University of Kentucky), 2025)

Opinion Mining of Erowid’s Experience Reports on LSD and Psilocybin-Containing Mushrooms - Ahmed Al-Imam; Riccardo Lora; Marek Motyka; E Marletta; Michele Vezzaro; Jerzy Moczko; Manal M. Younus; Michał Michalak (Drug Safety, 2025)

Psilocybin therapy might help frontline pandemic workers (The Brown University Psychopharmacology Update, 2025)

Psychedelic-assisted therapy: An overview for the internist. - Barnett BS; Mauney EE; King F. (2025)

Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder - Guy M. Goodwin; Ania Nowakowska; Merve Atli; Boadie W. Dunlop; David Feifel; David J. Hellerstein; Lindsey Marwood; Zainib Shabir; Sunil Mistry; S. C. Stansfield; Emma Teoh; Joyce Tsai; et al. (The Journal of Clinical Psychiatry, 2025)

Evaluating the Influence of CYP450 Enzyme Inducers on the Efficacy of Psilocybin as a Treatment for Neuropsychiatric Disorders (Abstract ID: 167358) - Elmira Zolali; Mahfuz Sakib; Jenny L. Wilkerson; Lance Richard McMahon; Samuel Obeng (Journal of Pharmacology and Experimental Therapeutics, 2025)

Correction: Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis. - Otto ME; van der Heijden KV; Schoones JW; van Esdonk MJ; Borghans LGJM; Jacobs GE; van Hasselt JGC. (2025)

Irremediable Psychiatric Suffering, a Potential Indication for Psilocybin Treatment - Metten Somers; Floortje E. Scheepers (American Journal of Psychiatry, 2025)

Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy. - Belitzky E; Ravani Carvalho LV; Taylor M; Ortiz CN; Baum L; Fiellin DA; Lustberg MB. (2025)

Sociodemographic and mental-health characteristics of psychedelic-assisted therapy participants: Latent class analysis of a cross-sectional, purposive online sample - Petrovitch D; Hosford S; Littlefield AK; Austin-Robillard H. (PsyArXiv, 2025)

Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms - Hodge A; Forsyth A; Noorani T; Muthukumaraswamy S; Rolleston A; McHugh P. (PsyArXiv, 2025)

Sociodemographic and mental-health characteristics of psychedelic-assisted therapy participants: Latent class analysis of a cross-sectional, purposive online sample (PsyArXiv, 2025)

Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms (PsyArXiv, 2025)

Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report - John Perna; Justin Trop; Roman Palitsky; Zachary Bosshardt; Helen Vantine; Boadie W. Dunlop; Ali John Zarrabi (BMC Psychiatry, 2025)

A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research. - Yaden DB; Graziosi M; Owen AM; Agin-Liebes G; Aaronson ST; Allen KE; Barrett FS; Bogenschutz MP; Carhart-Harris R; Ching THW; Cosimano MP; Danforth A; et al. (2025)

A review of psychedelics trials completed in depression, informed by European regulatory perspectives. - Silva F; Butlen-Ducuing F; Guizzaro L; Balabanov P. (2025)

The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: A Survey Based Experiment. - Hitchins K; Reynolds J. (PsyArXiv, 2025)

Psilocin, A Psychedelic Drug, Exerts Anticonvulsant Effects Against PTZ- and MES-Induced Seizures in Mice via 5-HT1A and CB1 Receptors: Involvement of Nitrergic, Opioidergic, and Kynurenine Pathways - Mohammad Balabandian; Mohammad Amin Manavi; Ali Lesani; Razieh Mohammad Jafari; Hamed Shafaroodi; Neda Heidari; Javad Mirnajafi-Zadeh; Alireza Foroumadi; Arya Afrooghe; Ahmad Reza Dehpour (Pharmacology Research & Perspectives, 2025)

The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: A Survey Based Experiment. (PsyArXiv, 2025)

Exploring factors associated with the intensity of a mystical experience following naturalistic psychedelic use: A retrospective survey. - Romeo B; Kervadec E; Fauvel B; Strika-Bruneau L; Amirouche A; Verroust V; Piolino P; Benyamina A. (2025)

Development and validation of a HPLC-DAD method for determining the content of tryptamines in methanolic extracts of fruiting bodies of mushrooms belonging to species of the Psilocybe genus. - Yasmo Perez JP; Chegwin Angarita C; Saldarriaga Ochoa OD; Urrego Restrepo SA. (2025)

Psychedelics and Suicide-Related Outcomes: A Systematic Review. - Meshkat S; Malik T; Zeifman R; Swainson J; Zhang Y; Burback L; Winkler O; Greenshaw AJ; Claire Reichelt A; Vermetten E; Erritzoe D; Jha MK; et al. (2025)

Anaesthetic implications of psilocybin and lysergic acid diethylamide: what is old is now new: A narrative review on psychedelics and anaesthesia. - Dave M; Shore R; Cupido T; Haley C; Clinkard D. (2025)

Psychedelic-assisted Therapy as a Promising Treatment for Irritable Bowel Syndrome. - Mauney E; King F; Burton-Murray H; Kuo B. (2025)

Quantitative natural language processing markers of psychoactive drug effects: A pre-registered systematic review. - Ahuja S; Zaher F; Palaniyappan L. (2025)

Esse quam Videre: Critical Reflections on the Use of Psilocybin as an Adjuvant in Psychedelic-Assisted Psychotherapy - Fábio Nogueira Pereira; Ana Carina Rothechedl Cavalieri; João Paulo Crespo Ferreira; Kelly De Souza Ventura (Polymatheia., 2025)

Development of Psilocybe Mushroom Species Reference Material-Cultivation Parameters and Chemical Profiles - Coleton Windsor; Anna E. Kreynes; Jeff Chilton; William A Chioffi; Christopher Niebergall; Kelsey Dodds (Journal of AOAC International, 2025)

Akzeptanz psilocybin-assistierter Therapie in den deutschsprachigen Ländern - Hartter; Nina; Däumichen; Marvin; Schmidt; Christopher; Wolff; Max; Gründer; Gerhard; Jungaberle; Henrik (edoc Publication server (Humboldt University of Berlin), 2025)

CORRECTION: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. (2025)

Psilocybin alters visual contextual computations - Aqil M; de Hollander G; Vreugdenhil N; Knapen T; Dumoulin SO. (bioRxiv, 2025)

A qualitative analysis of the psychedelic mushroom come-up and come-down - Ari Brouwer; Joshua K. Brown; Earth Erowid; Fire Erowid; Sylvia Thyssen; Charles L. Raison; Robin Carhart-Harris (npj Mental Health Research, 2025)

Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats - Fuini E; Chang A; Ortiz RJ; Nasseef T; Edwards J; Latta M; Gonzalez E; Woodward TJ; Bradshaw HB; Axe B; Maheswari A; Cavallaro N; et al. (bioRxiv, 2025)

Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges. - Lucido MJ; Dunlop BW. (2025)

The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials. - Hogea L; Tabugan DC; Costea I; Albai O; Nussbaum L; Cojocaru A; Corsaro L; Anghel T. (2025)

Psilocybin as a Treatment for Repetitive Mild Head Injury: Evidence from Neuroradiology and Molecular Biology - Brengel EK; Axe B; Maheswari A; Abeer MI; Ortiz RJ; Woodward TJ; Walhof R; Utama R; Sawada C; Balaji S; Kulkarni PP; Bradshaw HB; et al. (bioRxiv, 2025)

Psilocybin mushroom stewardship: A qualitative inquiry into practices and priorities of “underground” psilocybin mushroom practitioners - Shannon Hughes; Lucia Terpak; Reilly Capps; Pam Peters; Nicole Lilly; Dylan Rivard (Journal of Psychedelic Studies, 2025)

Investigating novel pharmacological strategies for treatment-resistant depression: focus on new mechanisms and approaches. - de Miranda AS; C B Toscano E; Venna VR; Graeff FG; Teixeira AL. (2025)

Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report - Vanessa Fleury; Emilie Tomkova; Sabina Catalano Chiuvé; Louise Penzenstadler (Journal of Parkinson s Disease, 2025)

Beneficial effect of the combination psilocybin-semaglutide in a murine model of Steatotic Liver Disease - Martina Colognesi; Daniela Gabbia; A. Signor; Stefano Comai; Andrea Mattarei; Gianfranco Pasut; Franco Folli; Lucia Centofanti; S. La Rosa; G Finzi; M. Pappagallo; Paolo Manfredi; et al. (Digestive and Liver Disease, 2025)

Direct effects of psilocybin on serotonin receptors regulate lipid accumulation in hepatic cells and adipocytes - A. Signor; Martina Colognesi; Daniela Gabbia; Ilaria Zanotto; Y. Frion-Herrera; Stefano Comai; Andrea Mattarei; Gianfranco Pasut; Franco Folli; M. Pappagallo; Paolo Manfredi; S. De Martin (Digestive and Liver Disease, 2025)

Clinical Trial Comparing Psilocybin to Nicotine Patch for Tobacco Addiction - Matthew Weirick Johnson (Drug and Alcohol Dependence, 2025)

International Drug Policy Study Trends With Psychedelic Drugs: A Spotlight on Psilocybin, LSD, and MDMA - Myfanwy Graham; Wayne Hall; Rosalie Liccardo Pacula; David Hammond (Drug and Alcohol Dependence, 2025)

Latent Class Analysis of Changes in Substance Use and Depressive Symptoms following Naturalistic Psilocybin Use: Results from a Prospective Longitudinal Survey - Jérémie Richard; Sandeep M. Nayak; Nathan D. Sepeda; Albert Garcia-Romeu (Drug and Alcohol Dependence, 2025)

Source Localized Auditory Erp Sensory and Preattentive Correlates of Psilocybin-Induced Ego-Dissolution Related Effects - Destiny Carbello; Tomáš Páleníček (Drug and Alcohol Dependence, 2025)

Prevalence of Use of Psilocybin and MDMA in Multiple US Cities - Tamara A. Millay; Nae Won; Anna Wang; Joseph J. Palamar; Linda B. Cottler (Drug and Alcohol Dependence, 2025)

Oregon’s Emerging Psilocybin Services Workforce: An Environmental Scan - Kellie Pertl; Kim Hoffman; Adrianne R. Wilson-Poe; Jason B. Luoma; Alissa Bazinet; Sarann Bielavitz; Dennis McCarty; Christopher S. Stauffer; Cameron Wolf; P. Todd Korthuis (Drug and Alcohol Dependence, 2025)

Lifetime Psilocybin Use and Opioid Use Disorder in Pregnant and Non-Pregnant Women of Reproductive Age - Amanda L. Elmore; Marina Bolser; Matt Richey (Drug and Alcohol Dependence, 2025)

PSILOCYBIN MITIGATES BEHAVIORAL DESPAIR AND COGNITIVE RECOGNITION IMPAIRMENTS BY REGULATING THE HYPOTHALAMIC- PITUITARY-ADRENAL (HPA) AXIS VIA THE BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) SIGNALING PATHWAY MEDIATED BY THE ENDOCANNABINOID SYSTEM (ECS) (2025)

ANXIOLYTIC- AND PROCOGNITIVE-LIKE EFFECTS OF A30-DAY CHRONIC TREATMENT WITH A LOW NON-PSYCHEDELIC DOSE OF PSILOCYBIN IN C57BL/6J MICE (2025)

BEHAVIORAL PHENOTYPING AND METABOLOMIC COMPARISON OF CHEMICALLY SYNTHESIZED PSILOCYBIN AND PSYCHEDELIC MUSHROOM EXTRACT IN A ZEBRAFISH DEPRESSION MODEL (2025)

ASSOCIATIONS BETWEEN ESCITALOPRAM AND PSILOCYBIN THERAPY AND BRAIN RESTING-STATE FUNCTIONAL CONNECTIVITY IN MAJOR DEPRESSIVE DISORDER (2025)

EFFECT OF ACUTE PSILOCYBIN ON THERMAL AND NEUROPATHIC PAIN IN RODENTS (2025)

Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective. - Marazziti D; Weiss F; Gurrieri R; Russomanno G; Gambini M; Magnesa A; Coccoglioniti A; Perugi G (Expert review of neurotherapeutics, 2025)

Among Psychedelics, Only Psilocybin Has Demonstrated Benefit to Treat Depression. - Allen F. Shaughnessy (PubMed, 2025)

Low (micro)doses of 2,5-dimethoxy-4-propylamphetamine (DOPR) increase effortful motivation in low-performing mice. - Noback M; Kenton JA; Klein AK; Hughes ZA; Kruegel AC; Schmid Y; Halberstadt AL; Young JW. (2025)

Psychedelics in neuroinflammation: Mechanisms and therapeutic potential. - de Deus JL; Maia JM; Soriano RN; Amorim MR; Branco LGS. (2025)

Psychedelic-assisted treatment for substance use disorder: A narrative systematic review. - Piper T; Small F; Brown S; Kelleher M; Mitcheson L; Rucker J; Young AH; Marsden J. (2025)

Correction: Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'. - O'Connor S; Godfrey K; Reed S; Peill J; Rohani-Shukla C; Healy M; Robbins T; Frota Lisboa Pereira de Souza A; Tyacke R; Papasyrou M; Stenbæk D; Castro-Rodrigues P; et al. (2025)

Study Protocol for ‘PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity’ - Sorcha O'Connor; Kate Godfrey; Sara Reed; Joseph Peill; Cyrus Rohani-Shukla; Mairead Healy; Trevor W. Robbins; Ana Frota Lisboa Pereira de Souza; Robin J. Tyacke; Maria Papasyrou; Dea Siggaard Stenbæk; Pedro Castro-Rodrigues; et al. (Cureus, 2025)

Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity. - Kinderlehrer DA. (2025)

Psychiatric Treatments with Short-Duration Psychedelics and AI-Driven Behavioral Monitoring. - Kargbo RB. (2025)

Suicide of a patient shortly after psilocybin-assisted psychedelic therapy: A case report - Felix Müller; Thomas Sauer; Corina Hänny; Markus Mühlhauser; Undine E. Lang (Psychiatry Research, 2025)

Effects of Psilocybin on Mouse Brain Microstructure - Paloma C. Frautschi; Ajay Paul Singh; Nicholas A. Stowe; Sean M. Grady; Zarmeen Zahid; Matthew I. Banks; John-Paul J. Yu (American Journal of Neuroradiology, 2025)

Exploring Psilocybe cubensis Strains: Cultivation Techniques, Psychoactive Compounds, Genetics and Research Gaps. - Kurzbaum E; Páleníček T; Shrchaton A; Azerrad S; Dekel Y. (2025)

Mice lacking the serotonin transporter do not respond to the behavioural effects of psilocybin - James J Gattuso; Carey Wilson; Shanshan Li; Anthony J. Hannan; Thibault Renoir (European Journal of Pharmacology, 2025)

Molecular insights into the modulation of the 5 HT2 A receptor by serotonin, psilocin, and the G protein subunit Gqα - Niklas Viohl; Ali Asghar Hakami Zanjani; Himanshu Khandelia (FEBS Letters, 2025)

Acute effects of psilocybin on attention and executive functioning in healthy volunteers: a systematic review and multilevel meta-analysis. - Yousefi P; Lietz MP; O'Higgins FJ; Rippe RCA; Hasler G; van Elk M; Enriquez-Geppert S. (2025)

Experiential dimension of psilocybin-assisted therapy training: Necessity or hindrance to wider accessibility? - Louis Plourde; Sue-Ling Chang; Houman Farzin; Jean-François Stephan; Jean-Sébastien Fallu; Michel Dorval (Journal of Psychedelic Studies, 2025)

When death is desired: A case of MAiD & the CL psychiatrist. - Ganguly A; James M; Alici Y (Palliative & supportive care, 2025)

A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression - Central Institute of Mental Health; Mannheim (ClinicalTrials.gov, 2025)

Catalyst for change: Psilocybin's antidepressant mechanisms-A systematic review. - Liebnau J; Betzler F; Kerber A. (2025)

Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications. - Melani A; Bonaso M; Biso L; Zucchini B; Conversano C; Scarselli M. (2025)

Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial - Shakila Meshkat; Richard J. Zeifman; Kathleen E. Stewart; Reinhard Janssen-Aguilar; Wendy Lou; Rakesh Jetly; Candice M. Monson; Venkat Bhat (PLoS ONE, 2025)

Transformative Therapies for Depression: Postpartum Depression, Major Depressive Disorder, and Treatment-Resistant Depression. - Richardson E; Patterson R; Meltzer-Brody S; McClure R; Tow A. (2025)

Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights. - Henderson I; Elsaadany R; Chan G; Bajaj V; Duarte D; Goodman S; Grunstein M; Vadhan NP; Duarte RA. (2025)

Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities. - Krawczyk N; Miller M; Gu EY; Irvine N; Ramirez E; Santaella-Tenorio J; Lippincott T; Bogenschutz M; Bunting AM; Meacham MC (Addiction (Abingdon, England), 2025)

Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis. - Otto ME; van der Heijden KV; Schoones JW; van Esdonk MJ; Borghans LGJM; Jacobs GE; van Hasselt JGC. (2025)

Age- and estrous-dependent effects of psilocybin in rats - Zylko A; Rakoczy R; Roberts B; Wilson M; Powell A; Page A; Heitkamp M; Fiest D; Jones J; McMurray M. (bioRxiv, 2025)

What are the benefits and harms of classical psychedelics (psilocybin and LSD) for treating anxiety, depression, and existential distress in people with life-threatening diseases? - Amin Sharifan (Cochrane Clinical Answers, 2025)

A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers. - Roman Palitsky; Jessica L. Maples-Keller; Caroline Peacock; Boadie W. Dunlop; Tanja Mletzko; George H. Grant; Charles L. Raison; Sam Chao; Isabelle Shub; Michal Mendelbaum-Kweller; Liam Smolyar; Deanna M. Kaplan; et al. (Psychotherapy, 2025)

Study finds encouraging results in psilocybin treatment for TRD patients - Valerie A. Canady (Mental Health Weekly, 2025)

Social pain: A systematic review on interventions. - Brooks BM; Cordero FJ; Alchermes SL; Brooks BM. (2025)

A systematic review of participant diversity in psychedelic-assisted psychotherapy trials. - Haft SL; Downey AE; Raymond-Flesch M; Fernandes-Osterhold G; Bradley ER; O'Donovan A; Woolley J. (2025)

Cell-type specific transcriptional modulation by psilocybin induces sustained plasticity in mouse medial prefrontal cortex - Schuler H; Zhou D; Savignac C; Cvetkovska V; Tse Y; Meccia J; Lopez J; Harutyunyan AS; Ragoussis J; Bzdok D; Bagot RC. (bioRxiv, 2025)

A Psilocybin Experience Gone Wrong: The Importance of Psychedelic Assisted Psychotherapy - Fernando Espí Forcén (Journal of Psychoactive Drugs, 2025)

Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management. - Strand NH; Whitney M; Johnson B; Dunn T; Attanti S; Maloney J; Misra L; Gomez D; Viswanath O; Emami E; Leathem J. (2025)

Neurobiological mechanisms of antidepressant properties of psilocybin: A systematic review of blood biomarkers. - Constantino JL; van Dalfsen JH; Massetti S; Kamphuis J; Schoevers RA. (2025)

Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation - Mona Irrmischer; Drew Puxty; Barış Onur Yıldırım; J.B. Deijen; Hessel Engelbregt (Psychopharmacology, 2025)

Psilocybin induces sex- and context-specific recruitment of the stress axis - Cook SG; Lee S; Ference E; Shi Y; Rojas-Carvajal M; Hen R; Bains JS; Füzesi T; Turi GF. (bioRxiv, 2025)

Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review. - Erkizia-Santamaría I; Horrillo I; Meana JJ; Ortega JE. (2025)

Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor. - Sutherland I; Ho MF; Croarkin PE. (2025)

Single-nucleus transcriptomics reveals cell type-specific and time-dependent effects of psilocybin and ketamine on gene expression - Liao C; O’Farrell E; Weiner AM; Qalieh Y; Savalia NK; Girgenti MJ; Kwan KY; Kwan AC. (bioRxiv, 2025)

Elucidating the Phase I metabolism of psilocin in vitro. - Chen J; Wang Z; Yong CY; Goh EML; Moy HY; Chan ECY. (2025)

Perturbing whole-brain models of brain hierarchy: an application for depression following pharmacological treatment - Socoró Garrigosa M; Sanz Perl Y; Kringelbach ML; Carhart-Harris R; Vohryzek J; Deco G. (bioRxiv, 2025)

Mushroom poisoning: An updated review. - Tuğcan MO; Akpınar AA. (2025)

The Right to 'Trip:' Navigating Psilocybin-Assisted Psychotherapy Under the Right to Try Pathway - Caitlyn S. Greenspun (eYLS (Yale Law School), 2024)

Psilocybin-containing mushrooms as a prospective therapeutic for Parkinson’s disease. Pre-clinical study - Godinho de Oliveira; Elisabete (Southern Cross Research Portal (Southern Cross University), 2024)

Clinical use of psilocybin in mental disorders:: a bibliometric analysis in Scopus and Web of Science - Jimmy Nicolas Hernandez Herrera; Marian Daniela Guio Sierra (Dialnet (Universidad de la Rioja), 2024)